Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Company and personnel

20 April 2021

GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update

08 April 2021

GenSight Biologics Announces the Filing of its 2020 Universal Registration Document

08 April 2021

Annual General Meeting on April 29, 2021

26 March 2021

GenSight Biologics successfully raises €30 million in an oversubscribed private placement with European and US institutional investors

25 March 2021

GenSight Biologics launches a reserved offering of c. €25 million by means of an accelerated bookbuilding process

22 Mar 2021 - 25 Mar 2021

BioEurope Spring – virtual

10 March 2021

GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021

06 Apr 2021 - 09 Apr 2021

Cell & Gene Meeting on the Mediterranean, virtual

22 Feb 2021 - 25 Feb 2021

4th Annual Gene Therapy for Rare Disorders – virtual

18 Feb 2021

OIS Gene Therapy Innovation Showcase – virtual

  • View previous 9 articles
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 19
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page